The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
From targeted metagenomics on almost 300 soil samples, researchers saw evidence for microbiome gene clusters associated with natural product biosynthesis in NYC parks.
The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The researchers identified 122 potential immune response drivers that could serve as targets for drug research efforts.
The researchers identified new combinations of mutated genes and drugs that could provide the platform for future cancer therapies.
Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.
Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.
Researchers link genetic links between education and smoking and longevity.
In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.